Lupus nephritis: new progress in diagnosis and treatment
C Yu, P Li, X Dang, X Zhang, Y Mao, X Chen - Journal of autoimmunity, 2022 - Elsevier
Systemic lupus erythematosus (SLE) is a chronic multifactorial autoimmune disease that
affects many organs, including the kidney. Lupus nephritis (LN) is a common manifestation …
affects many organs, including the kidney. Lupus nephritis (LN) is a common manifestation …
Immunosuppressive treatment for proliferative lupus nephritis
DJ Tunnicliffe, SC Palmer, L Henderson… - Cochrane Database …, 2018 - cochranelibrary.com
Background Cyclophosphamide, in combination with corticosteroids, has been first‐line
treatment for inducing disease remission for proliferative lupus nephritis, reducing death at …
treatment for inducing disease remission for proliferative lupus nephritis, reducing death at …
Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients
RJ Cheng, AJ Xiong, YH Li, SY Pan… - Frontiers in cell and …, 2019 - frontiersin.org
Mesenchymal stem cells (MSCs) have a potently immunosuppressive capacity in both
innate and adaptive immune responses. Consequently, MSCs transplantation has emerged …
innate and adaptive immune responses. Consequently, MSCs transplantation has emerged …
Pragmatic approaches to therapy for systemic lupus erythematosus
W Xiong, RG Lahita - Nature Reviews Rheumatology, 2014 - nature.com
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with substantial
clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and …
clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and …
Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials
BACKGROUND: Lupus nephritis accounts for∼ 1% of patients starting dialysis therapy.
Treatment regimens combining cyclophosphamide with steroids preserve kidney function …
Treatment regimens combining cyclophosphamide with steroids preserve kidney function …
Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double‐blind, placebo …
Objective Pegloticase is used for the treatment of severe gout, but its use is limited by
immunogenicity. This study was undertaken to evaluate whether mycophenolate mofetil …
immunogenicity. This study was undertaken to evaluate whether mycophenolate mofetil …
Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors?
The pathogenesis of the autoimmune rheumatological diseases including rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE) is complex with the involvement of …
arthritis (RA) and systemic lupus erythematosus (SLE) is complex with the involvement of …
Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications
CH Feldman, FM Marty, WC Winkelmayer… - Arthritis & …, 2017 - Wiley Online Library
Objective While infection burden is high among patients with systemic lupus erythematosus
(SLE), there is uncertainty about whether infection rates differ by immunosuppressive drug …
(SLE), there is uncertainty about whether infection rates differ by immunosuppressive drug …
Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy
JAJG van den Brand, PR van Dijk… - Journal of the …, 2014 - journals.lww.com
Abstract Recently published Kidney Disease Improving Global Outcomes (KDIGO)
guidelines recommend limiting the use of immunosuppressive drugs in idiopathic …
guidelines recommend limiting the use of immunosuppressive drugs in idiopathic …